March 26, 2015



ODISCOVERY C

O TRANSLATIONAL

DEDUCATION

OCLINICAL


O INFRASTRUCTURE

Agenda Item #7 Consideration of Recommendations from the Grants Working Group on the Preclinical Development Award Applications

#### Lisa Kadyk, Ph.D.

Senior Science Officer California Institute for Regenerative Medicine

## **PCD Awards: Purpose**



- Fund early preclinical development of successful stem-cell based translational projects.
- Upon successful completion of award: ready for PA 15-01, Late-Stage Preclinical Development.
- Final RFA issued under the "1.0" process.



# **PCD Awards: Eligibility**

Two key scientific eligibility criteria:

#### **Development Candidate (DC)**

✓ A single DC that derives from or targets stem cells.

#### **Readiness**

- Convincing, reproducible disease-modifying activity in relevant models
- Preliminary assessments of safety, mechanism-of-action
- ✓ Reproducible, scalable research-grade production of candidate



### **PCD Awards: Objective and Scope**

**Objective:** Carry out activities needed to conduct a well-prepared pre-IND meeting with the FDA at the end of the award

#### **In-Scope Activities:**

- GMP manufacturing process development
- Dose, regimen, route of administration studies
- Pharmacokinetic, pilot safety and mechanism of action studies
- Selection of target indication
- Preparation of clinical development plan, draft protocol
- Conduct of pre-IND meeting with FDA



## **PCD Awards: Funding Information**

### **Award Information**

- Up to \$40M total, 5 to 8 awards
- 30 months, up to \$5-8M justifiable total project costs

### **Co-Funding**

1:1 matching funding required <u>if</u> DC not identified with prior CIRM funding



### **PCD Awards: Review Criteria Highlights**

#### 1) Should the proposed therapeutic be developed?

- Significance: Competitive with standard of care
- Scientific Rationale: Potential for clinical benefit in targeted indication

#### 2) Can the proposed plan achieve the RFA Objective?

- Readiness: Convincing preclinical efficacy, preliminary safety and mechanism-ofaction, reproducible production of DC
- Design and Feasibility: Project plan complete, timeline realistic
- Assets, Collaborations, Environment: MTAs, patents, contracts, equipment and facilities.

#### 3) Is this the right team to execute the plan?

PI and Team: Experience in team leadership, preclinical development



## Scoring by Grants Working Group (GWG)

- Tier 1 (scores  $\geq$  75): recommended for funding
- Tier 2 (scores 65-74): moderate quality or consensus on merit not reached

• Tier 3 (scores  $\leq$  64): not recommended for funding



## PCD Priorities for Programmatic Consideration

The following priority areas were called out in the RFA:

- Cell therapies, especially if derived from pluripotent stem cells or directly reprogrammed cells
- Potentially transformative approaches to unmet medical needs
- 25% co-funding (if DC identified using CIRM funding)
- 1:1 industry co-funding (if DC not identified using CIRM funding)



### **CIRM Recommendations and Rationale**

#### Tier 1 Applications: Fund

- CIRM supports the GWG assessment
- Five awards, \$15.8MM
- \$3.25MM co-funding

### Tier 2 and Tier 3 Applications: Do not fund

- Applicants may consider submitting improved proposals, addressing review comments
- Opportunities:
  - CIRM 2.0 Translational/Early Preclinical program announcement (anticipated for Summer 2015)
  - PA 15-01 Partnering Opportunity for Late Stage Preclinical Projects (Open Now)



